New oral anticoagulants in atrial fibrillation: Questions and answers for the emergency physician;Los nuevos anticoagulantes orales en la fibrilación auricular: Preguntas y respuestas para el urgenciólogo

Emergencias

Volumn 25, Issue 2, 2013, Pages 123-136

  Suero Méndez, Coral ^a,b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Grupo de Arritmias SEMES   (Spain)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; New oral anticoagulants; Rivaroxaban; Thromboprophylaxis

Indexed keywords

EID: 84876481451     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Camm AJ, Kirchhof P, Lip G, Schotten U, Savelieva I, Sernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-29.
2. Camm AJ, Lip G, De Caterina R, Savelieva J, Atar D, Hohnlosen SH, et al. 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-47.
3. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talaj U. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic embolization in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74-90.
4. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurty MS, et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. Can J Cardiol. 2012;28:125-36.
5. Wann LS, Curtis AB, January CT, Elleborgen KA, Lowe JE, Estes NA, et al. 2011 ACCF/AHA/HRS Focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104-23.
6. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezkovitz MD, Jackman WM, et al. 2011 ACCF/AHA/HRS Focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:1330-7.
7. Martín A, Fernández I, Coll-Vinent B, Tercedor Sánchez C, Del Arco Galán C. Manejo de los pacientes con fibrilación auricular en los servicios de urgencias hospitalarios (actualización 2012). Documento de Consenso del Grupo de Arritmias Cardiacas de la Sociedad Española de Medicina de Urgencias y Emergencias (SEMES) y de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (SEC). Emergencias. 2012;24:300-24.
8. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-72.
9. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546-54.
10. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295-304.
11. De Caterina R, Husted S, Wallentin L. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007;28:880-913.
12. Granger CB, Alexander JH, McMurray JJ, Lopro RD, Hylek EM, Hame M, et al for the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365:981-92.
13. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in Atrial Fibrillation-Thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-41.
14. Pradaxa R. Ficha Técnica o Resumen de las Características del Producto. (Consultado 1 Agosto 2011). Disponible en: www.ema.europa.eu
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
16. Wartak SA, Bartholomew JR. Dabigatran: will it change clinical practice? Cleveland Clinic J Med. 2011;78:657-64.
17. Xarelto R. Ficha Técnica o Resumen de las Características del Producto. (Consultado 10 Enero 2012). Disponible en: www.ema.europa.eu
18. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-7. e1
19. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.
20. Agencia Española de Medicamentos y Productos Sanitarios AEMPS. Dabigatran (Pradaxa®) y riesgo de hemorragia: Nuevas recomendaciones de vigilancia de la función renal. (Consultado 27 Octubre 2011). Disponible en: http://www.aemps.gob.es/informa/notasInformativas/ medicamentosUsoHumano/seguri dad/2011/docs/NIMUH_ 21-2011.pdf
21. European Medicines Agency updates on safety of Pradaxa. EMA/CHMP/903767/2011. (Consultado 18 Noviembre 2011). Disponible en URL: http://www.ema.europa.eu/docs/en_GB/document_ library/Press_release/2011/11/WC5 00117818.pdf
22. Eriksson BI, Borris LC, Friedman RJ, Hass S, Huisman MV, Kakar AK, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboproohylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75.
23. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al; RECORD2 Investigators. Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-9.
24. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86.
25. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016-23.
26. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.
27. Huisman MV, Lip GY, Diener HC, Brueckmann M, Van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertaintiesin routine practice. Thromb Haemost. 2012;107:838-47.
28. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107:985-97.
29. HemoclotR thrombin inhibitor assay (Hyphen BioMed, Neuville-sur-Oise, Francia). (Consultado 10 Mayo 2012). Disponible en: www.hyphen-biomed.com
30. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012;38:178-84.
31. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011;9:226-8.
32. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Weinlingh M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32:267-71.
33. Samama MM, Amiral J, Guinet C. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104:1078-9.
34. Tripodi A. Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Thromb Haemost. 2011;105:735-6.
35. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Pareteti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-76.
36. Escolar G, García J, Lopez F, Roldán V. Guía sobre los nuevos anticoagulantes orales. Madrid: Sociedad Española de Hematología y Hemoterapia/ Sociedad Española de Trombosis y Hemostasia; 2012.
37. Marlu R, Hodaj E, Paris A, Albadalejo P, Cracowski JK, Peanod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran, rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-24.
38. García JA, Quintana M, Enrique R. Conceptos básicos y errores comunes sobre la coagulación y el manejo de la anticoagulación en el paciente con traumatismo. Emergencias. 2012;24:134-42.
39. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller MR, Levi M. Reversal of rivaroxaban and dabigatran by Prothrombin Complex Concentrate. A randomized placebo controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-79.
40. Levy JH, Key NS, Azran MS. New oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010;113:726-45.
41. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia. 2007;62:1154-60.
42. You JJ. Antithrombotic Therapy for Atrial Fibrillation. Chest. 2012;141(Supl e):531S-e575S.
43. Van Ryn J, Litzenburger T, Watermanet A. Dabigatran anticoagulant activity is safely neutralized by an antibody selective to dabigatran in in vitro and in vivo models. Poster presented at 60th Annual Scientific Session of the American Collegue of Cardiology Congress at New Orleans. JACC. 2011;57:E1130.
44. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365:2039-40.
45. Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol. 2011;72:593-603.
46. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72.
47. Ruiz-Nodar JM, Marín F, Roldán V. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv. 2012:5:459-66.
48. Lip GY, Huber K, Andreotti F, Arnsen H, Airaksinen JK, Cuisset T, et al. Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting. Eur Heart J. 2010;31:1311-8.
49. Huber K, Airaksinen KJ, Cuisset T. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost. 2011;106:569-71.
50. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572-84.
51. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Yany S, Xavier D, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-6.
52. Hohnloser SH, Oldgren J, Yang S, Wallenti L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669-76.
53. Uchino K, Hernández AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397-402.
54. Gibson CM, Mega JL, Burton P, Goto S, Vecheugt F, Bode C, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLASACS 2. TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161:815-21.
55. Mega JL, Braunwald E, Wiviott SD, Bassand JB, Bhatt DL, Bode C, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.
56. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. New oral anticoagulants in Atrial fibrillation and Acute Coronary Syndromes. ESC Working Group on Thrombosis-Task Force on Anticoagulants in heart disease position paper. J Am Coll Cardiol. 2012;59:1413-25.
57. Alonso de Leciñana M, Egido JA, Casado I. Guía para el manejo del infarto cerebral agudo. Neurología. 2011;294:21.
58. Quintana M, Borobia A, Pérez S, Rodríguez C, García JA. Estudio de coste-efectividad del empleo de concentrado de complejo protrombínico en urgencias para evitar las complicaciones de la sobredosificación de anticoagulantes. Emergencias. 2012;24:113-120.
59. Maegdefessel L, Linde T, Krapiec F, Halnilton K, Steinseifer U, Van Ryn J, et al. In vitro comparison of dab-igatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res. 2010;126:e196-200.
60. McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141:1410-6.
61. Kaeberich A, Reindl I, Raaz U, Maeyde Jessel L, Vogt A, Lind T, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivar-oxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis. 2011;32:417-25.
62. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Harter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163:931-7.